Prognostic value of expression of RANK and c-Src in patients with breast cancer with bone metastasis.

• DOI: 10.1200/jco.2011.29.15_suppl.e21024
• Publication Date: 2017-02-23T13:58:03Z
• Authors: X. Qu; L. Zhang; Y. Teng; Y. Zhang; J. Liu; L. Xu; J. Qu; K. Hou; X. Yang; Y. Liu
• Keywords: Log-rank test

e21024 Background: Receptor activator for nuclear factor kappa B ligand/receptor (RANKL/RANK) pathway is critical RANK-expressing cancer cells to home bones, and c-Src progression. However, there are no data currently available about the effect of RANK/c-Src on breast patient prognosis. This study was aimed evaluate RANK prognosis in metastatic patients. Methods: expression were evaluated by immunohistochemical staining primary tissues 102 patients with distant metastasis. The median follow-up period 40 (range 7-143) months. relationship between and/or clinical outcome explored. log-rank test Kaplan-Meier method used survival analysis. Multivariate analysis performed according Cox proportional hazards model. Results: positive rates 47.1% 54.9%, respectively, tissues. All developed metastases, which 62 bone metastases. Patients showed significantly poorer progression-free (p=0.023) disease-specific (p=0.001). Similarly, also (p=0.044) (p=0.017). Subgroup demonstrated that significant difference completely related occurrence Furthermore, co-expression correlated metastasis-free rate (p=0.007) (p=0.002) metastasis an independent predictor (RR=2.281; 95%CI: 1.105-4.710; p=0.026) (RR=4.434; 1.697-11.586; p=0.002). Conclusions: Co-expression might be poor